We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Ms
Wai Yee
James
Topic: Inflammatory and Immune System Subtopic: Inflammatory and Immune System (all Subtopics) Disease: Immunology and inflammation
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Vitamin D - the sunshine vitamin - is best known for its effects on bone health. Profound deficiency causes rickets, a condition that causes the bones on children to become soft and weak, which, in turn, can lead to bone deformities. More moderate deficiency, commonly seen in the UK during winter and spring, can make people more susceptible to respiratory infections. Respiratory infections cause 20% of GP consultations, 300,000 hospital admissions and 30,000 deaths per year. Patients with chronic obstructive pulmonary disease (COPD) are at high risk of such infections. Studies have shown that vitamin D 'switches on' the production of natural antibiotic substances that can kill viruses and bacteria in cells that fight infection. One small study, originally designed to look at the effects of vitamin D on bone health has shown that patients receiving high-dose vitamin D were 3 times less likely to have cold and 'flu symptoms than those who received placebo (dummy pill). The primary aim of the study is to determine whether vitamin D supplementation is a cost-effective and acceptable way to reduce acute respiratory illness in patients with COPD.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2014 Results article in https://doi.org/10.1016/S2213-2600(14)70255-3 results
You can take part if:
You may not be able to take part if:
1. Current diagnosis of asthma2. Known clinically significant bronchiectasis3. Known sarcoidosis, hyperparathyroidism, nephrolithiasis, active tuberculosis, vitamin D intolerance, liver failure, renal failure, terminal illness, lymphoma or other malignancy not in remission for 3 years4. Any other condition that, in an investigator's judgement, might compromise patient safety or compliance, interfere with evaluation or preclude completion of the study5. COPD requiring long-term oxygen therapy 12 hours per day6. Taking benzothiadiazine derivative, cardiac glycoside, carbamazepine, phenobarbital, phenytoin or primidone7. Taking dietary supplement containing vitamin D up to 2 months before first dose of IMP8. Treatment with any investigational medical product or device up to 4 months before first dose of IMP9. Breastfeeding, pregnant or planning a pregnancy10. Baseline corrected serum calcium greater than 2.65 mmol/L11. Baseline serum creatinine greater than 125 micromol/L12. Upper respiratory tract infection (URTI) or COPD exacerbation up to 28 days before first dose of IMP13. Inability to use spirometer14. Inability to complete symptom diary
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Ms
Wai Yee
James
The study is sponsored by Barts and The London School of Medicine and Dentistry and funded by National Institute for Health Research.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 7831
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
